CD79A and COVID-19: As indicated in the original condensed manuscript [Schasfoort, R.B.M., et al., 2021], a combined measurement of the anti-RBD IgM, IgG and IgA specific levels of CoViD-19 patients is possible in a single experiment using Surface Plasmon Resonance imaging (SPRi).